Company: SYRA
Filing Date: 2025-09-09
Form Type: PRE 14A
Source: 0001641172-25-026901
Chunk: 26

Company: Syra Health Corp
Filing Date: 2025-09-09
Form: PRE 14A
Chunk 26
---
4, calculated in accordance with 
 Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation – Stock Compensation. See Note        
 12, “Common Stock Options” in the notes to the Company’s consolidated financial statements for the year ended December               
 31, 2024 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 11, 2025 for more information regarding    
 the Company’s accounting for share-based compensation plans.                                                                         |
| (3) | On                                                                                                                                   
 November 14, 2024, the Company granted to each of its directors an option to purchase shares of the Company’s common stock           
 under the 2022 Plan, having an exercise price of $0.3683 per share, exercisable over a 10-year term, to each of its non-employee     
 directors, as follows: (1) Andrew Dahlem – 11,581 shares of common stock; (2) Ketan Paranjape – 19,303 shares of common              
 stock; (3) Avutu Reddy – 15,442 shares of common stock; (4) Vijayapal Reddy – 15,442 shares of common stock; and (5)                 
 Sherron Rogers – 11,581 shares of common stock. 25% of the options vested immediately on the date of grant and the balance           
 of the options vest in 12 equal monthly installments.                                                                                |
| (4) | On                                                                                                                                   
 April 25, 2025, Andrew Dahlem resigned from the Board of Directors for personal reasons.                                             |

Bonus Arrangements

Pursuant to the terms of the executive employment agreements described above, the Company, through the Board, has the discretion to determine the amounts of the annual incentive bonus payments which executives may receive.

| 17 |

<div align='center'>EQUITY COMPENSATION PLAN INFORMATION</div>

On April 11, 2022 and October 18, 2022, our board of directors adopted, and our stockholders, respectively, approved, the Syra Health Corp. 2022 Omnibus Equity Incentive Plan which was subsequently amended by our board of directors and stockholders on April 19, 2023 (“ 2022 Plan”). We intend to use the 2022 Plan to provide incentives that will enable us to attract, retain, and motivate employees, officers, consultants, and directors. We have reserved an aggregate 1,041,667